Publication | Open Access

Pathologic complete response (pCR) to neoadjuvant treatment with or without atezolizumab in triple-negative, early high-risk and locally advanced breast cancer: NeoTRIP Michelangelo randomized study

Advanced Breast CancerBreast OncologyOncologyPathologic Complete ResponsePathologyImmune Checkpoint InhibitorBreast CancerCancer TreatmentMedicineNeotrip Michelangelo